A Phase II Multicenter Study of Stereotactic Body Radiation Therapy (SBRT) Combined With Anlotinib and Bimepolizumab in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
Latest Information Update: 09 Apr 2026
At a glance
- Drugs Bemarituzumab (Primary) ; Catequentinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
Most Recent Events
- 20 Mar 2026 New trial record